$KMPH Travis Mickle, CEO: Turning to the next slide looking more specifically at KP415. As I mentioned, there was no substantial issues or safety concerns that were raised on our last meeting with the FDA on August 13th. We do have a tentative date, December 1st of this year, in which we could also meet with the agency for a late cycle review meeting. This meeting would only be called if it was necessary to do so. So, that would be to identify any improve ability issues, or just to confirm, you know that there are no issues. So, either way, we will be explaining and sending along what happens at that meeting along to investors and shareholders in order for you to know essentially how that is progressing. That is effectively the approvability point with the FDA supposed to know whether the product would be approvable or not from then on.